Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01281631 · ClinicalTrials.gov registry record · Phase 2
A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
A Phase 2 study of Amyotrophic Lateral Sclerosis, sponsored by Neuraltus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
- 17
- Study locations
NCT01281631: Completed Phase 2 study of Amyotrophic Lateral Sclerosis, sponsored by Neuraltus Pharmaceuticals.
NCT01281631 is a Phase 2 study of Amyotrophic Lateral Sclerosis that has completed, run by Neuraltus Pharmaceuticals. The registered enrollment target is 136 participants, below the 897-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (85% lower). The trial reports 17 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01281631, a Phase 2 study of Amyotrophic Lateral Sclerosis, has completed, sponsored by Neuraltus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
- 17
- Study locations
Study Summary
This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study of NP001 in subjects with ALS.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG NP001
Study Locations (17)
California
- UC, Irvine - Irvine
- UCLA - Los Angeles
- California Pacific Med Center Forbes Norris MDA/ALS Research and Treatment Center - San Francisco
New York
- Columbia University - New York
- SUNY Upstate Medical University, Syracuse - Syracuse
North Carolina
- Carolinas Medical Center - Charlotte
- Duke University, Dept of Neurology - Durham
Arizona
- Mayo Clinic, Scottsdale - Scottsdale
Florida
- Mayo Clinic, Jacksonville - Jacksonville
Georgia
- The Emory Clinic - Atlanta
Kansas
- University of Kansas Medical Center, Landon Center on Aging - Kansas City
Kentucky
- University of Kentucky, Department of Neurology - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2011-02 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
What the finished NCT01281631 record still lists
NCT01281631 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, below the 897-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01281631 lists 17 locations in 13 states (California, New York, North Carolina).
Frequently Asked Questions
What is clinical trial NCT01281631 about?
NCT01281631 is a clinical study titled "A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)". This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study of NP001 in subjects with ALS.
What is the current status of trial NCT01281631?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2011-02. Estimated completion is 2012-09.
What conditions does trial NCT01281631 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.
What interventions are being tested in trial NCT01281631?
The interventions under investigation include: Placebo (DRUG), NP001 (DRUG).
Who is sponsoring clinical trial NCT01281631?
This trial is sponsored by Neuraltus Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01281631 being conducted?
This trial has 17 study locations across Arizona, California, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01281631's enrollment target sits among peer trials
136 37th of 102 higher than 66 of 102 other Amyotrophic Lateral Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Amyotrophic Lateral Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
RECRUITING · Phase 2
-
HEALEY ALS Platform Trial - Master Protocol
RECRUITING · Phase 2
-
RAPA-501 Therapy for ALS
RECRUITING · Phase 2
-
A Study of Ranolazine in ALS
RECRUITING · Phase 2
-
Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia